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BACKGROUND & AIMS:

Patients with Crohn’s disease (CD), but not ulcerative colitis (UC), of shorter duration have higher
rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease
duration. Little is known about the association between disease duration and response to other
biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratiﬁed by
disease duration.

METHODS:

We analyzed data from a retrospective, multicenter, consortium of patients with CD (n [ 650) or UC
(n [ 437) treated with vedolizumab from May 2014 through December 2016. Using time to event
analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (£2 years duration) and later-stage (>2 years) CD
or UC. We used Cox proportional hazards models to identify factors associated with outcomes.

RESULTS:

Within 6 months initiation of treatment with vedolizumab, signiﬁcantly higher proportions of
patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR
(43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After
adjusting for disease-related factors including previous exposure to TNF antagonists, patients
with early-stage CD were signiﬁcantly more likely than patients with later-stage CD to achieve
clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02–2.49), CSFR (aHR, 3.39; 95%
CI, 1.66–6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06–3.39). In contrast, disease
duration was not a signiﬁcant predictor of response among patients with UC.

CONCLUSIONS:

Patients with CD for 2 years or less are signiﬁcantly more likely to achieve a complete response,
CSFR, or endoscopic response to vedolizumab than patients with longer disease duration.
Disease duration does not associate with response vedolizumab in patients with UC.

Keywords: Inﬂammatory Bowel Disease; Integrin; Monoclonal Antibody Therapy; Time.
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Abbreviations used in this paper: aHR, adjusted hazard ratio; CD, Crohn’s
disease; CI, conﬁdence interval; CSFR, corticosteroid-free remission; HR,
hazard ratio; IBD, inﬂammatory bowel disease; TNF, tumor necrosis factor; UC, ulcerative colitis.
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rohn’s disease (CD) and ulcerative colitis (UC) are
inﬂammatory bowel diseases (IBD) that result in
chronic inﬂammation of the gastrointestinal tract with
periods of remission alternating with relapse.1,2 It is
increasingly recognized that IBD, and CD in particular,
are progressive diseases in which patients accumulate
bowel damage over time that can lead to irreversible
complications.3–5 There seems to be an optimal window
of opportunity in which early effective intervention may
improve outcomes and alter the natural history of the
disease, akin to the evolving practice in rheumatoid
arthritis.6,7
Accumulating evidence suggests that treatment with
biologics targeting tumor necrosis factor (TNF)-a may be
more effective when initiated early in the disease course.
In a post hoc analysis of the PRECiSE 2 trial of certolizumab in CD, patients with disease duration less than 2
years had an 82% response rate at 26 weeks, compared
with 59% among those with longer disease duration.8
Similar ﬁndings emerged from post hoc analyses of the
CHARM trial of adalimumab in CD, where higher clinical
remission rates at 56 weeks were seen among patients
with disease duration less than 2 years (43%) compared
with 2–5 years (30%) or greater than 5 years (28%),
even after controlling for potential confounding factors,
such as prior TNF antagonist exposure.9
Whether this treatment-modifying effect of early
disease duration is unique to the TNF antagonist drug
class or extends to other treatment agents (eg, antiintegrins) is not clear. A post hoc analysis of the
ENCORE trial of natalizumab in CD found that disease
duration 3 years was associated with a higher proportion of patients in clinical remission at 12 weeks than
the overall treatment population (52% vs 38%).10 No
studies published to date have evaluated response and
remission rates to vedolizumab stratiﬁed by disease
duration.
We aimed to evaluate the impact of disease duration
on vedolizumab effectiveness using a multicenter consortium cohort study of the real-world experience with
vedolizumab. We analyzed rates of clinical and endoscopic remission in patients with CD and UC treated with
vedolizumab, comparing those with shorter disease
duration (2 years) with those with longer-standing (>2
years) disease.

C

Methods
Study Design
This is a retrospective review of the VICTORY Consortium registry.11 In brief, this is a multicenter collaborative research group repository where outcomes are
pooled for patients with IBD treated with biologics.
Institutional review board approval was obtained from
each site for ongoing data collection and transfer. Data
were collected individually by sites using a standardized
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What You Need to Know
Background
Patients with Crohn’s disease (CD), but not ulcerative
colitis (UC), of shorter duration have higher rates of
response to tumor necrosis factor antagonists than
patients with longer disease duration, but little is
known about the association between disease duration and response to other biologic agents. We
analyzed data from patients with CD or UC treated
with vedolizumab and used time to event analyses to
compare rates of clinical remission, corticosteroidfree remission (CSFR), and endoscopic remission
between patients with early-stage (2 years duration) and later-stage (>2 years) CD or UC.
Findings
Patients with CD for 2 years or less were signiﬁcantly
more likely to achieve a complete response, CSFR, or
endoscopic response to vedolizumab than patients
with longer disease duration. Disease duration did
not associate with response vedolizumab in patients
with UC.
Implications for patient care
Patients given a diagnosis of CD should begin treatment with anti-TNF agent or vedolizumab as soon as
possible.

data collection form and transferred (after deidentiﬁcation) to the coordinating site (University of California,
San Diego) for data compilation and analysis. The current
analysis represents data collected between May 2014
and December 2016. The results of this study are reported in accordance with the Strengthening the
Reporting of Observational Studies in Epidemiology
guidelines for cohort studies.12

Variables
Data on variables of interest were collected including:
patient characteristics (age at diagnosis, age at vedolizumab initiation, gender, smoking status, body mass index), disease characteristics (prior hospitalizations, prior
surgeries, disease-related complications or extraintestinal manifestations, and phenotype classiﬁed according to the Montreal classiﬁcations for CD and UC),
and treatment history (steroids, immunomodulators, and
TNF antagonists; duration of use; indication for discontinuation; and complications). Variables of interest speciﬁc to vedolizumab use were baseline disease severity
(endoscopic, radiographic, or clinical assessments),
concomitant treatments (steroids and/or immunomodulators), infusions (dates, intervals, premedications), and
follow-up assessments (endoscopic, radiographic, or
clinical assessments). Clinical assessments were classiﬁed as severe versus nonsevere based on physician
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global assessment, where mild or moderate severity
were classiﬁed as nonsevere. The primary variable of
interest was disease duration, deﬁned as a dichotomous
variable. Shorter duration was deﬁned as 2 years and
longer duration as >2 years at the time of vedolizumab
initiation. This deﬁnition is consistent with most prior
data on the impact of disease duration on the efﬁcacy of
biologics.8,9

Participants
Individuals were included in the current analysis if
they met the following criteria: (1) conﬁrmed diagnosis
of CD or UC based on clinical and endoscopic or radiographic data, (2) active clinical symptoms attributed to
CD or UC before starting vedolizumab, and (3) had at
least 1 clinical and/or endoscopic follow-up after initiation of therapy. Patients started on vedolizumab for
indeterminate colitis or pouchitis, or those in clinical
remission at the time of starting vedolizumab (eg, patients with CD transitioned from natalizumab to vedolizumab for safety or initiated on vedolizumab for
postoperative prophylaxis of CD) were excluded.

Outcomes
The primary outcomes of interest were the cumulative
rates for clinical remission, corticosteroid-free remission
(CSFR), or endoscopic remission at 6 months. Timing of
assessments for response followed routine practice standards as dictated by local sites with no predetermined or
standardized time-point of assessment. Clinical assessments for remission were performed based on physician
global assessment, where remission was deﬁned as complete resolution of all CD- or UC-related symptoms by
treating physician evaluation. The assessment of CSFR
(performed only in patients on prednisone or budesonide
at the time of initiation of vedolizumab) was deﬁned as
tapering off steroids completely, achieving clinical
remission, and no repeat steroid prescription within 4
weeks of tapering. Endoscopic remission was deﬁned as
the absence of ulcers and/or erosions in CD or a Mayo
endoscopic score of 1 in UC.13,14 Endoscopic categorization was done by local study investigators and was
reveriﬁed by a coordinating study investigator (P.S.D.)
using deidentiﬁed endoscopy reports, with any discrepancies resolved through consensus between the study
sites and the coordinating site.

Statistical Analysis
Continuous variables were presented as means and
standard deviations, or as medians and interquartile
ranges based on data distribution. Categorical and binary
variables were presented as proportions or percentages.
For the comparison of baseline continuous variables, we
used the independent sample t test (2 group comparisons)

Vedolizumab Treatment in Early IBD 2499

or 1-way analysis of variance with Bonferroni correction
(3 or more group comparisons). For the comparison of
baseline binary variables, we used the Pearson chi-square
or Fisher exact tests. Primary and secondary outcomes
were described quantitatively with Kaplan-Meier survival
and time-to-event analyses. Data were collected at clinical
follow-up times determined by each treating physician,
and 6-month cumulative outcomes were used in this study
to maximize available data. A sensitivity analysis was
performed by transforming disease duration into a categorical variable (2 years, >2 years to 5 years, and >5
years), and outcomes were described quantitatively with
Kaplan-Meier survival and time-to-event analyses to understand if the deﬁnition for early disease in CD could be
extended to 5 years.
Cox proportional hazards regression analyses were
performed to identify independent predictors of treatment outcomes. All baseline variables from the univariable analyses with a P value of < .20 were ﬁtted and a
backward model selection approach was taken where the
variable with the highest P value was sequentially selected
out until all remaining variables in the model had a P value
of < .05. Prior TNF antagonist exposure was included in all
multivariable models, irrespective of P value. An assessment of interaction terms was then performed and interactions were retained if they had a P value of < .05.
Hazard ratios (HR) with 95% conﬁdence interval (CI)
are presented for independent predictors where HR <1
indicated a predictor was associated with a reduced
probability for achieving the outcome and HR >1 indicated a predictor was associated with an increased
probability for achieving the outcome. Two-sided P
values < .05 were considered statistically signiﬁcant.
Statistical analyses were performed using Stata statistical
software (College Station, TX).

Study Sponsor
Takeda Pharmaceuticals provided funding for statistical support to analyze the data. Takeda Pharmaceuticals and associated employees did not have access to any
of the data, and all data analyses were performed at the
University of California San Diego by the VICTORY Consortium investigators or statisticians.

Results
Crohn’s Disease: Demographics
A total of 650 patients with CD were included. In the CD
group, there were signiﬁcant differences in baseline disease and treatment-related characteristics between those
with disease duration 2 years and those with duration
greater than 2 years (Table 1). Patients with longer disease
duration had higher rates of CD-related complications
including stricturing and penetrating disease (70% and
38% vs 39% and 23%, respectively; P < .05 for both

2500 Faleck et al

Clinical Gastroenterology and Hepatology Vol. 17, No. 12

Table 1. Baseline Demographics of Patient Cohorts
CD
2 y (n ¼ 62)
Age, y, median (IQR)
Male, n (%)
CRP, median (IQR)
Albumin, median (IQR)
BMI, median (IQR)
Hospitalized in previous year, n (%)
CD phenotype, n (%)
Stricturing or penetrating disease
Fistulizing disease
Prior surgery
UC extent, n (%)
E1
E2
E3
Disease severity, severe, n (%)
Steroid refractory/dependent, n (%)
TNF antagonist failure, n (%)
Number of prior TNF antagonist
agents, n (%)
0
1
2þ
Concomitant steroids, n (%)
Concomitant IM, n (%)

29
29
3.1
4.0
23.7
32

UC

>2 y (n ¼ 588)

(23–44)
(47)
(1–10)
(3.6–4.3)
(20–28.8)
(52)

24 (39)
14 (23)
22 (35)

37
243
5
3.9
23.7
203

(27–52)
(41)
(1–18)
(3.6–4.2)
(21–28.6)
(34)

414 (70)
222 (38)
377 (64)

P value
.07
.42
.34
.74
.71
.01

2 y (n ¼ 109)

>2 y (n ¼ 328)

31
57
1.1
3.9
23
28

(24–52)
(52)
(0.4–5.4)
(3.6–4.3)
(21.2–28)
(26)

41
161
2.3
4.0
25
82

(29–57)
(49)
(0.7–7.8)
(3.7–4.3)
(21.8–29)
(25)

4
33
72
42
56
61

(4)
(30)
(66)
(39)
(51)
(56)

18
123
187
98
152
185

(5)
(38)
(57)
(30)
(46)
(56)

42
51
16
65
44

(38)
(47)
(15)
(60)
(40)

101
144
83
174
103

(31)
(44)
(25)
(53)
(31)

P value
< .01
.58
.36
.16
.86
.90

< .01
.02
< .01
.23

21 (34)
25 (40)
37 (60)

202 (34)
220 (37)
455 (77)

14
27
21
32
19

46
128
414
265
251

(23)
(44)
(34)
(52)
(31)

(8)
(22)
(70)
(45)
(43)

.53
.68
< .01
< .01

.35
.08

.06
.38
1.00
.05

.27
.10

BMI, body mass index; CD, Crohn’s disease; CRP, C-reactive protein; IM, immunomodulator; IQR, interquartile range; TNF, tumor necrosis factor; UC, ulcerative
colitis.

comparisons). A higher percentage of longer duration patients had failed TNF antagonists (77% vs 60%; P < .01),
and 70% of those in the longer disease duration group
previously had failed at least 2 TNF antagonists versus 34%
in the shorter disease duration group (P < .01).

Crohn’s Disease: Cumulative Rates and
Predictors of Remission
The cumulative rates for clinical remission, CSFR,
and endoscopic remission for CD at 6 months were
Table 2. Remission Rates at 6 Months Stratiﬁed by Disease
Duration
Remission rates
Crohn’s disease
Clinical remission, %a
Corticosteroid-free
remission, %a
Endoscopic healing, %a
Ulcerative colitis
Clinical remission, %
Corticosteroid-free
remission, %
Endoscopic healing, %

2 y (n ¼ 62)
38
43

>2 y (n ¼ 588)
23
14

29
2 y (n ¼ 109)
35
22

13
>2 y (n ¼ 328)
33
20

16

22

Signiﬁcant (P < .05) on log-rank analyses.

a

signiﬁcantly higher in the early disease duration group
than in the longer disease duration group (Table 2,
Figure 1). When further stratifying the long disease
duration into >2 years to 5 years versus >5 years,
no differences were seen between these 2 groups
across any of the primary endpoints (Supplementary
Figure 1).
On multivariable analyses for CD, disease duration 2
years remained a signiﬁcant predictor of clinical remission (adjusted HR [aHR], 1.59; 95% CI, 1.02–2.49), CSFR
(aHR, 3.39; 95% CI, 1.66–6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06–3.39) (Table 3).

Ulcerative Colitis: Demographics
A total of 437 patients with UC were included. In
contrast to CD, there were few differences in baseline
demographic characteristics between the early and
longer disease duration of UC groups (Table 1). There
was a comparable distribution of disease extent according to the Montreal classiﬁcation between the 2
groups, a similar number of steroid-refractory or
steroid-dependent patients, and a comparable percentage of TNF antagonist naive patients (44% in both
groups). Notably, among those who had failed a prior
TNF antagonist, there was a higher percentage of individuals in the longer disease duration group who
had failed 2 or more TNF antagonist medications (25%
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Figure 1. Cumulative rates of remission stratiﬁed by disease duration 2 years or >2 years. (A) Clinical remission. (B)
Corticosteroid-free remission. (C) Endoscopic remission.

vs 15%; P ¼ .05) than in the shorter disease duration
group.

Ulcerative Colitis: Cumulative Rates and
Predictors of Remission
Among patients with UC, there were no signiﬁcant
differences in any of the outcomes between those with
disease duration 2 years and those with longer disease
duration (Table 2). Univariable and multivariable
analyses were not performed for UC because initial timeto-event analyses revealed no differences in outcomes
between early and longer disease duration groups.

Discussion
In this multicenter consortium study, we observed
that treatment with vedolizumab in the ﬁrst 2 years after
diagnosis of CD is associated with higher rates of clinical,
corticosteroid-free, and endoscopic remission than
treatment initiated later in the disease course. This
improved treatment response was seen across all of the
study endpoints in CD, and persisted after controlling for
other predictors of treatment outcome, including prior
TNF antagonist therapy. In contrast, no association between disease duration and treatment outcome was seen
in patients with UC.
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Table 3. Multivariable Predictors of Treatment Outcomes in Crohn’s Disease
Predictors of treatment outcomes
in Crohn’s disease

Unadjusted HR (95% CI)

Clinical remission
Stricturing or penetrating phenotype
Disease severity (severe vs nonsevere)
Hospitalized in previous year
Disease duration 2 y
TNF antagonist exposure
Corticosteroid-free remission
Albumin
TNF antagonist exposure
Disease duration 2 y
Endoscopic remission
CRP
Albumin
Disease severity (severe vs nonsevere)
Disease duration 2 y
TNF antagonist exposure

0.58
0.40
0.66
1.69
0.51

(0.44–0.77)
(0.28–0.56)
(0.49–0.90)
(1.09–2.61)
(0.34–0.77)

Adjusted HR (95% CI)
0.69
0.53
0.71
1.59
0.64

(0.51–0.92)
(0.43–0.65)
(0.52–0.97)
(1.02–2.49)
(0.42–0.98)

1.47 (0.89–2.43)
0.43 (0.22–0.85)
2.99 (1.59–5.64)

1.76 (1.04–2.97)
0.40 (0.20–0.80)
3.39 (1.66–6.92)

0.97
2.29
0.46
1.89
0.63

0.98
1.70
0.59
1.90
0.95

(0.96–0.99)
(1.52–3.45)
(0.32–0.66)
(1.12–3.18)
(0.36–1.12)

(0.96–0.99)
(1.14–2.55)
(0.45–0.77)
(1.06–3.39)
(0.52–1.72)

NOTE. Variables entered in the multivariable models before backward selection was performed included those with P < .2. TNF antagonist exposure was included
in all models irrespective of P value at each step. For clinical remission, variables included gender, hospitalized within previous 1 year, CRP, albumin, structuring/
penetrating phenotype, ﬁstulizing disease, disease severity, and concomitant steroids. For corticosteroid-free remission, variables included gender, CRP, albumin,
ﬁstulizing disease, and disease severity. For endoscopic remission, variables included hospitalized within previous 1 year, CRP, albumin, structuring/penetrating
phenotype, ﬁstulizing disease, disease severity, concomitant steroids, and combination therapy with immunomodulator.
CI, conﬁdence interval; CRP, C-reactive protein; HR, hazard ratio; TNF, tumor necrosis factor.

In recent years, there has been an intense interest in
early, aggressive treatment of CD, to reduce the longterm morbidity associated with progressive bowel
damage.15 Early intervention is thought to target CD in a
“window of opportunity” before irreparable bowel
damage sets in.16 A lower percentage of patients in our
study in the early CD group had ﬁstulizing or penetrating
complications, which supports this hypothesis. A second
theory invokes different immune responses in early
versus late CD,17 including differential T-cell immune
responses to interleukin-12 stimulation in children with
early versus late CD18 and increases in peripheral Thelper cell type 17 cells in patients with late versus early
CD.19 Finally, the microbiome plays an important role in
responsiveness to therapy in IBD,20 and treatment-naive
early IBD may have a distinct microbiota composition
that can impact therapy outcomes.21
The landmark “Step-up/Top-down” study22 was the
ﬁrst to show in a randomized controlled trial that early
aggressive therapy with combined inﬂiximab and
azathioprine was superior to conventional step-up
approach in early CD for achieving early remission.
Similarly, a post hoc analysis of the landmark SONIC
trial23 stratifying by disease duration demonstrated
higher efﬁcacy in achieving rigorous endpoints, such as a
composite of clinical remission, mucosal healing, and Creactive protein normalization in patients with CD
treated within 18 months of diagnosis.24 Similar ﬁndings
have been found with adalimumab and certolizumab
monotherapy in early CD.8,9 In contrast to TNF antagonist medications, immunomodulators have not been
shown to be more effective in early disease in achieving
remission and mucosal healing.25,26

Our data add to the growing literature on early intervention in CD and demonstrate that improved outcomes
with early treatment are not a limited class effect of TNF
antagonist therapy. Importantly, this effect was seen even
in a relatively refractory cohort, with 60% of patients with
CD treated early with vedolizumab already having failed at
least 1 TNF antagonist. This ﬁnding represents an important step in targeting disease modiﬁcation in CD, because
vedolizumab has also been shown to have an excellent
safety proﬁle,27,28 although studies with long-term followup are still needed. Therefore, while balancing the beneﬁts
of early intervention with the possible side effects of
increased duration of drug exposure, vedolizumab may be
an excellent candidate for early initiation.
In contrast to the emerging literature on the beneﬁts
of early intervention in CD, there is a paucity of data on
early intervention in UC, and whether UC is a progressive
disease like CD remains unclear. In a retrospective
cohort study of the early initiation of inﬂiximab or adalimumab within 3 years of UC diagnosis, Ma et al29 found
no difference in the rates of UC-related hospitalizations,
secondary loss of response, or colectomy between early
and late treatment groups. Similarly, Mandel et al30
found that early TNF antagonist use in CD, but not in
UC, was associated with decreased hospitalization rates.
We are also unaware of any post hoc analyses of clinical
trials in UC demonstrating any impact of disease duration on treatment efﬁcacy. Our data are consistent with
these prior retrospective studies in showing no difference between early and late initiation of vedolizumab on
short-term treatment outcomes in UC.
The reason for the differing impact of early treatment
in UC versus CD is not clear. One hypothesis is that
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demonstration of disease modiﬁcation in UC may require
a longer duration of follow-up. The risk of colorectal
malignancy has been shown to correlate with the intensity and longevity of endoscopic and histologic intestinal inﬂammation,31 and therapy that can effectively
promote and maintain mucosal healing may decrease the
long-term risk of colorectal cancer.32–35 Histologic healing as an independent endpoint has garnered signiﬁcant
attention in recent years36,37 and would be an interesting
endpoint for future evaluation in our cohort. Similarly,
chronic inﬂammation leading to bowel damage and
ﬁbrosis in UC may yield poorer functional outcomes
because of loss of luminal wall compliance and development of anorectal dysfunction and motility disorders.32,38 Whether early intervention with vedolizumab
and other agents can alter the natural history of UC and
prevent these complications needs to be explored further
in longitudinal studies.
The strengths of our study include the large, realworld, multicenter data set that represents a broad
population of individuals with IBD. Patients had detailed
clinical and endoscopic data collected using standardized
extraction methods. Our data are concordant with
studies of TNF antagonist medications in early IBD
showing a beneﬁt in early CD but not UC, but importantly
we extend these ﬁndings to vedolizumab, which has not
previously been observed.
Our study does have several important limitations. The
retrospective collection of data across multiple institutions and the lack of well-validated clinical indices for
measuring treatment remission may impact response estimates. Additionally, no central reading of endoscopies
was performed, but rereview of reports by a single study
investigator resulted in <5% reclassiﬁcation of endoscopic scoring. Furthermore, the follow-up time used for
the primary outcomes in this study was relatively short
and the rates of additional outcomes, such as surgeries
and hospitalizations, were too low for meaningful analysis. Further data collection is needed to assess the
durability of the improved response rates in the treatment
of early CD, and to assess for a possible impact on longterm outcomes in UC. Finally, important differences exist
in the disease phenotype and treatment experience of the
early versus late groups, especially in CD. Despite rigorous
multivariable modeling to control for these factors, there
remains the possibility of unmeasured confounders
impacting response and remission rates.
In summary, we found that vedolizumab-treated patients with CD with early disease (2 years) had significantly improved outcomes with higher rates of clinical,
corticosteroid-free, and endoscopic remission than
those with longer disease duration. In contrast, this
improvement was not seen in patients with UC with
short disease duration treated with vedolizumab. The
combined safety and efﬁcacy of vedolizumab makes it an
attractive candidate for early, aggressive intervention in
hopes of achieving lasting disease modiﬁcation. Further
studies are needed to explore the impact of early use of
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vedolizumab on long-term outcomes and its ability to
prevent disease progression in CD and UC.

Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://doi.org/10.1016/j.cgh.2018.12.040.
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Supplementary Figure 1. Cumulative rates of remission stratiﬁed by disease duration 2 years, >2 to 5 years, >5 years. (A)
Clinical remission (P ¼ .01 for 2 vs >5 years; P > .10 for all other comparisons). (B) Corticosteroid-free remission (P < .01 for
2 vs >5 years and P ¼ .02 for 2 vs >2 to 5 years; P > .10 for all other comparisons). (C) Endoscopic remission (P ¼ .02 for
2 vs >5 years and P ¼ .05 for 2 vs >2 to 5 years; P > .10 for all other comparisons).

